Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

Gevo Stock Could Be the Most Interesting Stock You’ve Never Geard About

By Will Ashworth, InvestorPlace Contributor
Gevo's been at the clean energy game for a long time with very little to show for it. Is now the time for GEV stock to shine?

7 Tickers to Put on Your Watch List NOW

By InvestorPlace Research Staff
I want to share my personal list of stocks to watch. Buy these when other investors are panicking, and you'll be glad you did.

Castor Maritime Is Attractive Yet Lacks Operational Strength

By Alex Sirois, InvestorPlace Contributor
CTRM stock has the allure of a cheap stock and an easily understandable business model but its past indicates trouble.

Churchill Capital Corp. IV Has Actually Made Investors Proud

By Will Ashworth, InvestorPlace Contributor
Churchill Capital Corp. IV lost 20% in the past week. But, CCIV stock has doubled since its July 2020 IPO. How's that stack up against peers?

Zomedica’s Knowns, Known Unknowns, and its Unknown Unknowns

By Dana Blankenhorn, InvestorPlace Contributor
Truforma uses acoustic radio waves to analyze the chemical composition of small samples, and can diagnose some common diseases of dogs and cats.

Tesla Stock to $3,000? How Cathie Wood’s ARKK Highlights a Growing Problem

By Thomas Yeung, CFA, InvestorPlace Markets Analyst
TSLA stock jumped 8% last week when ARKK ETF Cathie Wood announced a $3,000 target price. But that hides bad news for Tesla and ARKK.

7 Hot Penny Stocks for the Robinhood Traders

By Josh Enomoto, InvestorPlace Contributor
With the rise of trading apps like Robinhood and the power of social media, penny stocks have tremendous potential but the same risks remain.

Covid Fatigue Threatens to Derail Once Relevant Quidel

By Josh Enomoto, InvestorPlace Contributor
With everyone tired of Covid-19 lockdowns and protocols, it’s hard to see QDEL stock as a confident contrarian trade.

Wait for A Pullback Before Buying Brand-New Coupang Stock

By Thomas Niel, InvestorPlace Contributor
Touted as the "Amazon of South Korea," e-commerce play CPNG stock may be a better buy once some of the hype settles down.

Second Sight May Take Another Look at Giving Up Control

By Mark R. Hake, CFA
Second Sight Will Probably Take a Second Look at Giving Up Control. EYES stock will probably rise if the company backs off of the sale of 60% to Pixium Vision.

MGM Resorts International Makes for a Low-Risk Recovery Play

By Tom Kerr, InvestorPlace Contributor
MGM stock seems to be relatively low-risk recovery play as margins return to normal and cash flow increases.

Is Approval Even Enough for Ocugen Stock?

By Vince Martin, InvestorPlace Contributor
Ocugen's partner has shown promise with its Covid-19 vaccine. But with Ocugen getting just 45% of U.S. profits, that promise is priced into OCGN stock.

Valuation Concerns Loom Over Airbnb As It Clobbers Its Hotel Rivals

By Thomas Logue, CFA
Airbnb has strong tailwinds coming out of the pandemic, but an expensive valuation and a lack of profitability are big concerns.

7 Ways to Define a Blue-Chip

By Dana Blankenhorn, InvestorPlace Contributor
The ranks of blue-chip stocks are constantly changing, and what you call a blue-chip investment will also change as you age.

Profit from the Advent of Smart Transportation with Luokung Technology

By David Moadel, InvestorPlace Contributor
There's a good chance that you've never invested in the location-based services sector before, but now you can get started with LKCO stock.

Why the Social Finance Merger Deal With IPOE Stock Looks Undervalued

By Mark R. Hake, CFA
The Social Finance merger deal with IPOE stock looks undervalued. IPOE stock is potentially worth 30% more at $23.91 once the SPAC merger with Sofi closes.

VG Acquisition Stock: The Value’s in the DNA Vault, Not the Spit Kits

By Dana Blankenhorn, InvestorPlace Contributor
If 23andme is worth $3.5 billion, it's based on the long-term asset of its DNA database, not the cash it gets from consumers for its saliva testing kits.

Has Luminar Technologies Stock Reached a Must-Buy Discount Level?

By Josh Enomoto, InvestorPlace Contributor
LAZR stock absorbed a massive blow, succumbing with the technology sector. But is now the time to secure a big-time discount?

Tap the Brakes on Energy Stocks

By Louis Navellier, Editor, Growth Investor
As I discussed earlier this month, a handful of energy stocks have become market leader. But before you invest, I suggest you slow down.
Load More Articles